Works matching IS 13960296 AND DT 2025 AND VI 2025 AND IP 1
Results: 1
Efficacy and Safety of GR1802 in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial.
- Published in:
- Dermatologic Therapy, 2025, v. 2025, n. 1, p. 1, doi. 10.1155/dth/6903760
- By:
- Publication type:
- Article